中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2012年
7期
469-472
,共4页
氟哌噻吨%钙通道阻滞药%曲美布汀%马来酸盐类%肠易激综合征%Meta分析
氟哌噻噸%鈣通道阻滯藥%麯美佈汀%馬來痠鹽類%腸易激綜閤徵%Meta分析
불고새둔%개통도조체약%곡미포정%마래산염류%장역격종합정%Meta분석
Flupenthixol%Calcium channel blockers%Trimebutine%Maleates%Irritable bowel syndrome%Meta-analysis
目的 了解氟哌噻吨美利曲辛联合常规药物与单用常规药物治疗肠易激综合征(IBS)疗效的差异.方法 检索中国期刊全文数据库、中国维普全文数据库、PubMed外文期刊数据库,检出氟哌噻吨美利曲辛联合其他常规药物(匹维溴铵及马来酸曲美布汀)与单用常规药物治疗IBS的研究进行比较分析,并在此基础上进行异质性检验和合并效应量的估计.结果 共检出12项疗程为4～12周的氟哌噻吨美利曲辛联合其他常规药物治疗IBS的临床试验,其中6项研究提示氟哌噻吨美利曲辛联合匹维溴铵与单用匹维溴铵治疗比较,异质性检验x2=1.90,自由度(df)=5,P=0.86,I2=0,固定效应模型的合并比值比(OR)=7.92,95％ CI(4.85,12.95),提示联合优于单药治疗；另6项研究提示氟哌噻吨美利曲辛联合马来酸曲美布汀与单用马来酸曲美布汀治疗比较,异质性检验X2=5.60,df=5,P=0.35,I2=10.6％,固定效应模型OR=5.91,95％ CI(4.06,8.61),提示联合优于单药治疗.合并该12项研究提示氟哌噻吨美利曲辛联合其他常规药物与单用常规药物治疗比较,异质性检验x2=8.40,df=11,P=0.68,I2=0,固定效应模型OR=6.63,95％ CI(4.92,8.93).结论 氟哌噻吨美利曲辛联合其他药物治疗IBS的疗效优于单用其他常规药物,但仍需进一步高质量的研究验证.
目的 瞭解氟哌噻噸美利麯辛聯閤常規藥物與單用常規藥物治療腸易激綜閤徵(IBS)療效的差異.方法 檢索中國期刊全文數據庫、中國維普全文數據庫、PubMed外文期刊數據庫,檢齣氟哌噻噸美利麯辛聯閤其他常規藥物(匹維溴銨及馬來痠麯美佈汀)與單用常規藥物治療IBS的研究進行比較分析,併在此基礎上進行異質性檢驗和閤併效應量的估計.結果 共檢齣12項療程為4～12週的氟哌噻噸美利麯辛聯閤其他常規藥物治療IBS的臨床試驗,其中6項研究提示氟哌噻噸美利麯辛聯閤匹維溴銨與單用匹維溴銨治療比較,異質性檢驗x2=1.90,自由度(df)=5,P=0.86,I2=0,固定效應模型的閤併比值比(OR)=7.92,95％ CI(4.85,12.95),提示聯閤優于單藥治療；另6項研究提示氟哌噻噸美利麯辛聯閤馬來痠麯美佈汀與單用馬來痠麯美佈汀治療比較,異質性檢驗X2=5.60,df=5,P=0.35,I2=10.6％,固定效應模型OR=5.91,95％ CI(4.06,8.61),提示聯閤優于單藥治療.閤併該12項研究提示氟哌噻噸美利麯辛聯閤其他常規藥物與單用常規藥物治療比較,異質性檢驗x2=8.40,df=11,P=0.68,I2=0,固定效應模型OR=6.63,95％ CI(4.92,8.93).結論 氟哌噻噸美利麯辛聯閤其他藥物治療IBS的療效優于單用其他常規藥物,但仍需進一步高質量的研究驗證.
목적 료해불고새둔미리곡신연합상규약물여단용상규약물치료장역격종합정(IBS)료효적차이.방법 검색중국기간전문수거고、중국유보전문수거고、PubMed외문기간수거고,검출불고새둔미리곡신연합기타상규약물(필유추안급마래산곡미포정)여단용상규약물치료IBS적연구진행비교분석,병재차기출상진행이질성검험화합병효응량적고계.결과 공검출12항료정위4～12주적불고새둔미리곡신연합기타상규약물치료IBS적림상시험,기중6항연구제시불고새둔미리곡신연합필유추안여단용필유추안치료비교,이질성검험x2=1.90,자유도(df)=5,P=0.86,I2=0,고정효응모형적합병비치비(OR)=7.92,95％ CI(4.85,12.95),제시연합우우단약치료；령6항연구제시불고새둔미리곡신연합마래산곡미포정여단용마래산곡미포정치료비교,이질성검험X2=5.60,df=5,P=0.35,I2=10.6％,고정효응모형OR=5.91,95％ CI(4.06,8.61),제시연합우우단약치료.합병해12항연구제시불고새둔미리곡신연합기타상규약물여단용상규약물치료비교,이질성검험x2=8.40,df=11,P=0.68,I2=0,고정효응모형OR=6.63,95％ CI(4.92,8.93).결론 불고새둔미리곡신연합기타약물치료IBS적료효우우단용기타상규약물,단잉수진일보고질량적연구험증.
Objective To evaluate the efficacy difference between flupentixol and melitracen combined with conventional medicine and conventional drug alone in the treatment of irritable bowel syndrome (IBS).Methods Studies on flupentixol and melitracen combined with conventional medicine (pinaverium bromide and trimebutine maleate) and conventional medicine alone in the treatment of IBS were collected and reviewed through searching the Chinese Academic Journals Full-text Database,Chinese VIP Full-text Database and PubMed database.After that,the test for homogeneity and the combined effect test were estimated. Results A total of 12 clinical studies on flupentixol and melitracen combined with conventional medicine for four to twelve weeks in the treatment of IBS were collected six studies indicated the homogeneity test of flupentixol and melitracen combined with pinaverium bromide (x2 =1.90,df=5,P=0.86,I2 =0).For the fixed-effect model,the odds ratio was 7.92 and 95％ CI was between 4.85 and 12.95,which suggested the combined therapy was better.The other six studies indicated the homogeneity test of flupentixol and melitracen combined with trimebutine maleate (x2 =5.60,df=5,P =0.35,I2 =10.6 ％).For the fixed-effect model,the odds ratio was 5.91 and 95％ CI was between 4.06 and 8.61,which suggested the combined therapy was better.After merging the 12 studies it indicated the homogeneity test of flupentixol and melitracen combined with conventional medicine (x2 =8.40,df =11,P =0.68,I2 =0).For the fixed effect model,the odds ratio was 6.63 and 95％ CI was between 4.92 and 8.93.Conclusion The efficacy of flupentixol and melitracen combined with conventional medicine in the treatment of IBS was better than that of conventional medicine alone,however,still more high quality trials are needed for further confirmation.
